fexuprazan

potassium-competitive acid blocker

Also Known As:

1H-pyrrole-3-methanamine, 5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-N-methyl-; 5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-N-methyl-1H-pyrrole-3-methanamine; DWP-14012; DWP14012; abeprazan

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - fexuprazan: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - fexuprazan: 3

Related Diseases

1.	Gastritis 11/15/2023 - "In this study, 327 patients with acute or chronic gastritis who had one or more gastric erosions on endoscopy and subjective symptoms were randomized into three groups receiving fexuprazan 20 mg once a day (q.d.), fexuprazan 10 mg twice a day (b.i.d.), or placebo for 2 weeks. " 11/15/2023 - "The aim of this study was to assess the 2-week efficacy and safety of fexuprazan in patients with acute or chronic gastritis. " 11/15/2023 - "Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis." 08/01/2023 - "Ongoing clinical trials are evaluating fexuprazan for the prevention of NSAID-induced peptic ulcer disease, non-erosive GERD, and acute and chronic gastritis, as well as healing efficacy and maintenance of erosive esophagitis (EE). "
2.	Esophagitis 08/01/2023 - "Completed clinical trials of fexuprazan have demonstrated comparable efficacy to PPIs for the healing of erosive esophagitis and relief of GERD-related esophageal symptoms without concerning safety signals. " 11/28/2022 - "To compare fexuprazan to esomeprazole and establish its efficacy and safety in patients with erosive esophagitis (EE). " 11/28/2022 - "Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis." 08/01/2023 - "Ongoing clinical trials are evaluating fexuprazan for the prevention of NSAID-induced peptic ulcer disease, non-erosive GERD, and acute and chronic gastritis, as well as healing efficacy and maintenance of erosive esophagitis (EE). "
3.	Peptic Ulcer (Peptic Ulcers) 08/01/2023 - "Ongoing clinical trials are evaluating fexuprazan for the prevention of NSAID-induced peptic ulcer disease, non-erosive GERD, and acute and chronic gastritis, as well as healing efficacy and maintenance of erosive esophagitis (EE). "
4.	Gastroesophageal Reflux (GERD) 08/01/2023 - "Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease." 08/01/2023 - "Completed clinical trials of fexuprazan have demonstrated comparable efficacy to PPIs for the healing of erosive esophagitis and relief of GERD-related esophageal symptoms without concerning safety signals. "
5.	Non-Erosive Reflux Disease 08/01/2023 - "Ongoing clinical trials are evaluating fexuprazan for the prevention of NSAID-induced peptic ulcer disease, non-erosive GERD, and acute and chronic gastritis, as well as healing efficacy and maintenance of erosive esophagitis (EE). "

Related Drugs and Biologics

1.	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
2.	Esomeprazole (Nexium)